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A B S T R A C T
Objective: This systematic review examined the epidemiology of otitis media (OM) in children <6 years
within 90 developing and newly industrialised countries.
Methods: Literature searches (1992–2011), based onMEDLINE, EMBASE, WHO, Index Medicus, country-
speciﬁc websites, conferences, and the reference lists of included studies, yielded 11,413 records; 59 of
344 studies analysed were included in this review.
Results: The majority of the identiﬁed studies provided only a single timepoint for OM. In children <6
years of age, OM prevalence was found to be 9.2% in Nigeria, 10% in Egypt, 6.7% in China, 9.2% in India,
9.1% in Iran and 5.1–7.8% in Russia. Few studies examined the etiology of OM and the antibacterial
resistance. Themost common bacterial pathogens were S. pneumoniae,H. inﬂuenzae and S. aureus. A high
resistance to penicillin was reported in Nigeria and Turkey.
Conclusions: Despite the variability between the identiﬁed studies, this review indicates that OM and its
various sub-types remain a signiﬁcant burden in different settings. However, the heterogeneity of
studies and a general lack of reliable data made generalisation very difﬁcult.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Otitismedia (OM) isoneof themostcommonchildhood infections
in pre-school aged children [1] and a major cause of childhood
morbidity [2–5]. OM also represents the most frequent reason why
children are prescribed with antibiotics or undergo surgery in the
developed countries [6,7]. Moreover, in most of the countries
belonging todeveloping countries, no guidelines regarding the use of
antibacterial treatment in OM and respiratory tract infections exist
and in several countries, parents can purchase any antibacterial drug
in pharmacies without mandatory medical prescriptions.
OM is subdivided into several disease sub-categories: acute
otitis media (AOM), recurrent AOM, OM with effusion (OME) and
chronic suppurative OM (CSOM). AOM presents with local and
systemic signs and has a rapid onset [8,9], and is a leading cause of
antibacterial treatment for children in developed countries
[10,11]. OME can occur during the resolution of AOM once the
acute inﬂammation has resolved but bacteria may still be present
[12], while CSOM requires ongoing inﬂammation of the middle ear
leading to otorrhea persisting for at least two weeks and per-
foration of the tympanic membrane [13].
In general, OM can be caused by bacteria or viruses [14]. The
two leading bacterial pathogens are Streptococcus pneumoniae and
non-typeable Haemophilus inﬂuenzae (NTHi) [14–16]. Other im-
portant bacterial causes of OM are Staphylococcus aureus, Moraxella
catarrhalis and S. pyogenes [14,16]. In terms of causative agent, the
difference between OME and AOM is that the frequency of S.
pneumoniae is not as high, and H. inﬂuenzae and M. catarrhalis are
moderately more common.
It has been estimated recently that around 20,000 people die
annually from complications associated with OM, with the highest
mortality rates in the children <5 years of age [4]. Recurrent or
chronic formsof thedisease can lead toconsiderablehearing loss and
negatively affect learning ability and scholastic achievement [17].
It is well known that the prevalence of OM is increasing over
time; Auinger et al. have reported this observation from the US
during the 80s, attributed in part to the increase in child care and in
higher prevalence of allergic conditions [1,18]. While there is a
considerable body of work examining the treatment of OM [19–
21], limited research has been undertaken on the burden of OM in
developing and newly industrialised countries. A systematic
review of AOM in children from Latin America and the Caribbean
[2], a review of OM burden in children from Asia-Paciﬁc [5], and a
systematic review on global estimates for OM and related
conditions [4] were published previously.
To build on this work, we conducted a systematic review of the
epidemiology of OM, including all sub-categories, in children <6
years of age from90 developing and newly industrialised countries
covering Africa, China, India and South Asia, Russia and the
Commonwealth of Independent States (CIS), and the Middle East.
Our review focussed on incidence, prevalence, distribution of
pathogens and antimicrobial resistance in children with OM.
2. Materials and methods
2.1. Search strategy and eligibility criteria
This reviewwas restricted to a pre-deﬁned list of 90 developing
and newly industrialised countries (see Supplementary Material,Appendix A for a list of the countries included). These countries
covered 5 regions of interest: Africa, China, India and South Asia,
Russia and CIS, and the Middle East.
Children <6 years of age with a diagnosis of OM (any sub-
category) were the population of interest. Studies including a
wider age-range for participants were only included when they
reported separate results for those aged <6 years. Searches were
not limited by language or publication status.
Twenty-three electronic databases were searched from 1992 to
October 2011, includingMEDLINE, EMBASE, African IndexMedicus,
IndexMedicus for theEasternMediterraneanRegion, IndexMedicus
for South Asia Region, Western Paciﬁc Region Index Medicus.
Conference abstracts and relevant websites (e.g. Health Ministry
websites) were also searched. An example of search strategy for
MEDLINE is included in Supplementary Material, Appendix B.
The current review reports on the following outcomes:
incidence or prevalence or count of OM (any sub-category),
distribution of pathogens causing OM and antimicrobial resistance
and susceptibility of pathogens causing OM. Otitis externa and
labyrinthitis were excluded from this review.
Any study or data source reporting relevant outcome data were
included, for example, observational studies (e.g. cohort studies,
case-control studies, case series), country-speciﬁc/regional trials,
registries, guideline/guidance documents, and statistical data-
bases. We planned to investigate various subgroups of interest
(disease sub-categories, age-groups, vaccination status, HIV status,
malnutrition, diagnostic approach), but a paucity of data made
these analyses unfeasible.
2.2. Screening and data abstraction
Pairs of reviewers working independently screened the titles
and abstracts of the retrieved references for relevance and any
disagreements were resolved through consensus. Studies that
were potentially relevant (prevalence, incidence and mortality of
OM in children [aged <6 years] in the countries of interest, both
overall and in different patient groups; distribution of pathogens
and serotypes causing OM in the countries under consideration;
seasonal variation in the incidence rate of OM; rate of treatment
failure, antibiotic resistance, and hearing impairment from OM for
the countries under consideration; health resource use for OM;
health related quality of life for OMpatients, parents or care givers;
vaccination programmes and recommendation) or studies that
were in disagreement were ordered and the full article was
assessed for inclusion by one reviewer and checked by a second
reviewer. Any disagreements were resolved through discussion or
were checked by a third reviewer. Justiﬁcations for excluding
papers from the review were documented for all full papers
ordered for further inspection. Studies fulﬁlling all inclusion
criteria were included in the review.
Data abstraction sheets Microsoft Excel (version 2010) were
ﬁrst piloted on a small selection of studies. Subsequently, for each
study, data were abstracted by one reviewer and checked by a
second reviewer. Any disagreements were resolved by consensus.
2.3. Assessment of methodological quality
The risk of bias for included studies was assessed using the
Downs and Black 27 item checklist for the methodological quality
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for observational studies focused on the use of an appropriate
recruitment strategy, response rates, sample representativeness of
the general population, objective and reliable outcome measures,
use of a power calculation, appropriate use of statistical methods
and evidence of bias within the studies. The checklist was
completed independently by pairs of reviewers and any disagree-
ments were resolved by discussions. The results of the risk of bias
assessment were used for descriptive purposes to provide an
evaluation of the overall quality of the included studies and yield a
transparent method of recommendation for the design and
conduct of future studies. The results of the study quality
assessment carried out are detailed in Supplementary Material,
Appendix C.
2.4. Data synthesis and analysis
The heterogeneity of the included studies precluded statistical
pooling of data. Instead, results have been narratively analysed,
grouped into AOM and chronic/other OM, and ordered by region
and country to aid interpretation.
3. Results
A total of 11,413 records were retrieved through the searching
of 23 electronic databases and loaded into an EndNote library, from
which 59 publications (journal articles and governmental statis-
tics) were included in the review (Fig. 1). Publication dates ranged
from 1992 to 2011 and reported data for locations in Africa, India
and South Asia, China and Hong Kong, Middle East, and Russia
[3,23–80].[(Fig._1)TD$FIG]
Fig. 1. Flow of studies retrieved through electronic database searches.3.1. Incidence and prevalence
Fifty-nine publications were identiﬁed which provided some
measure of OM incidence and/or prevalence across ﬁve regions and
16 countries (Egypt, Nigeria, Ethiopia, China, Hong Kong, India,
Bangladesh, Pakistan, Saudi Arabia, Turkey, Oman, United Arab
Emirates, Iran, Yemen, Bahrain and Russia) [3,23–80]. For AOM,
there were ﬁve studies conducted in Africa, all from Nigeria [49–
53], 2 studies from India and South Asia [3,28], and 9 studies from
the Middle East [31–34,36,54–57] (Table 1). For chronic/other OM,
12 studies were from Africa [23,24,53,58–66], 3 were from China
and Hong Kong [25,26,74], 9 from India and South Asia [3,27,67–
73], 24 from the Middle East [30–47,56,75–79], and 1 from Russia
[48] (Table 2). These studies included different sub-categories of
OM, different study designs and ways of measuring OM. The
majority of studies consisted of small sample sizes and few
provided estimates of incidence or prevalence, but rather a count
of the number of OM cases over a single timepoint.
3.1.1. Africa
A study by Amusa et al. [23] aimed to measure community
prevalence of OM in a sample of 600 Nigerian children aged <12
years. This study found the prevalence of OM to be 14.7% (88/600),
with a peak in children 1–4 years of age (55/600; 9.2%). OM was
diagnosed as AOM, CSOM and OME in 11.8%, 2.5% and less than 1%
of children <12 years of age, respectively.
Khallaf et al. [24] used a data set of 75,789 acute respiratory
infections from 5 regions across Egypt among children <4 years of
age, and found that the prevalence of OM cases was about 10%
(8078/75,789), ranging from 8.2% (258/3145) for those <2 months
of age to 10.6% (2413/22,649) for the 2–11-month-olds and 10.8%
(5407/49,995) for the 1–4-year-olds.
Another eleven studies were found to report measures of OM
for Nigeria [49–53,58–63]; however, many of these were hospital-
based rather than population-based and contained small samples
(Tables 1 and 2).
3.1.2. China and Hong Kong
There were 2 studies from China included [25,26]. Both were
population-based and included relatively large samples. Wang
et al. and Zhang et al. found OME prevalence to be 6.7% (children
3–6 years of age) and 6.3% (91/1431; children 2–6 years of age),
respectively [25,26]. By age group, the prevalence was reported at
14.0% in 2-year-olds, 8.3% in 3-year-olds, 5.0% in 4-year-olds, 4.9%
in 5-year-olds and 2.8% in 6-year-olds [26].
3.1.3. India and South Asia
A study by Sophia et al. of pre-school children in rural India
provided population-based data from a relatively large sample of
800 children and found the prevalence of OM to be 9.2% (54/587) in
children 0–5 years old [27]. In Pakistan, Tariq et al. provided data
from an observational hospital-based study on the prevalence of
AOM in 1724 children<2 years of age [28]. The prevalence of AOM
was reported at 4.4% (75/1724) [28].
3.1.4. Middle East
A study by Zakzouk et al. (2002) from Saudi Arabia used data
from a large sample of 9540 children <12 years of age
(2054 children <4 years of age), collected from 70 health centres
across the kingdom [29]. The prevalence of AOM (otoscopic
criteria) was 1.05% (100/9540) in children <12 years of age, with a
higher value in children <4 years of age (1.95%; 40/2054).
A study by Naini et al. examined the link between parental
smoking and OME prevalence among children in Iran [30]. This
study used a large population-based sample of 3833 children aged
2–11 years (1833 pre-school children [2–6 year-olds]) and the
Table 1
Summary of studies reporting counts or incidence of AOM in children <6 years of age.
Region Country (study design) N Diagnosis Age; Count (%) Source
Africa Nigeria (cross-sectional) 617 AOM 0–12m; 23/53 (43.4%)
13–24m; 23/53 (43.4%)
25–36m; 7/53 (13.2%)
[49]
200 AOM 0–1 y; 12/64 (18.8%)
2–3 y; 24/64 (37.5%)
4–5 y; 16/64 (25.0%)
[50]
114 AOM 0–5 y; 77/114 (67%) [51]
200 AOM 0–11m; 13/200 (6.5%)
12–23m; 19/200 (9.5%)
24–35m; 2/200 (1%)
36–47m; 2/200 (1%)
48–60m; 1/200 (0.5%)
[52]
361 ASOM 0–1 y; 46/83 (55.4%)
2–5 y; 48/151 (31.8%)
[53]
South Asia Bangladesh (case series) 252 AOM 0–24m; 0.9 episodes per child-year [3]
Pakistan (cross-sectional) 1724 AOM 0–2 y; 75/1724 (4.3%) [28]
Middle East Saudi Aabia (cross-sectional) 9540 AOM <4 y; 40/2045 (1.96%) [54]
Turkey (case series) 120 AOM <1 y; 32 cases
1–2 y; 18 cases
2–4 y; 47 cases
4–6 y; 13 cases
[55]
Oman (cross-sectional state surveillance) NR AOM <5 y; 20,824 cases [31]
NR AOM <5 y; 18,376 cases [32]
NR AOM <5 y; 16,720 cases [33]
NR AOM <5 y; 14,489 cases [34]
NR AOM <5 y; 13,758 cases [56]
NR AOM <5 y; 10,970 cases [36]
Yemen (cross-sectional) 429 AOM <2 y; 145 cases
3–5 y; 101 cases
[57]
AOM, acute otitis media; ASOM, acute suppurative otitis media; m, month; y, year; N, sample size; NR, not reported.
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schoolers and 14.1% (283/2000) in school-aged children. Slightly
more children with OM had smoking parents (54%; 243/450).
Annual health reports from Oman, based on state surveillance,
provided reliable data for the total number of AOMand chronic OM
(COM) cases for 2003, 2004, 2005, 2007, 2008 and 2009
[31–37]. Oman’s total AOM cases in children <5 years of age
decreased from 20,824 in 2003 to 10,970 in 2009 and cases of COM
from 2951 in 2003 to 722 in 2009. Importantly, the 7-valent
pneumococcal conjugate vaccine (PCV) was introduced in Oman’s
National Immunization Program (NIP) in 2008 [81].
In Bahrain, similar surveillance data to Oman is provided by
the Salmaniya Medical Complex and covers suppurative unspeci-
ﬁed OM and OME (non-suppurative OM) for children <1 year
relative to all discharges for that age group (Table 2) [38–47]. Sim-
ilarly to Oman, PCV was introduced in Bahrain’s NIP in 2008
[81]. The vaccine is recommended to be administered in a 2-dose
schedule at 2 and 6 months of age followed by a booster at
15 months of age [82].
3.1.5. Russia
Lebedeva et al. provided both prevalence and incidence
estimates for 1991 and 1996 from Orenburg, Russia [48]. They
reported an overall prevalence estimate for all sub-categories of
OM between the ages 0–7 years at 5.1% for 1991, increasing to 7.8%
for 1996. They also reported separate prevalence estimates for
boys and girls and for different age groups: <1 year, 1–3 years and
4–7 years. Between 1991 and 1996 there were considerable
increases in OM incidence and prevalence overall and for each age
group and gender. The incidence estimates increased from 13.6 per
1000 children to 34.5 per 1000 children aged 0–7 years (Table 2).
The largest increases were in the <1 year age group, with 41.9%
increase for boys and 37.5% for girls, and 6.7% for boys and 4.9% for
girls, for incidence and prevalence, respectively. To account forthese relatively large increases in incidence and prevalence, the
authors point to improvements in surveillance activities, the use of
sensitive OM case deﬁnitions and improvements in access to care.
Of note, Russia introduced PCVs into its NIP in the beginning of
2014 [81].
3.2. Etiology
Six studies described the bacterial etiology of OM (the number
of cases of OM or its sub-categories where a pathogen could
be identiﬁed) in children <6 years of age [49,55,64,69,76,80]
(Table 3). These studies covered 3 regions and 5 countries (Nigeria,
Ethiopia, India, Saudi Arabia and Turkey) and included patients
with different subtypes of OM, used a range of study designs and
reported outcomes for several different age groups. Themajority of
studies were relatively small in terms of sample size. All studies
were conducted before the introduction of PCVs into the countries’
NIPs [81].
The most common bacterial pathogens were S. pneumoniae, H.
inﬂuenzae and S. aureus. The estimates from 4 studies reporting
data on S. pneumoniae ranged from 8.8% to 38% with little
consistency observed between the studies or between sub-
categories of OM [49,55,76,80]. H. inﬂuenzae prevalence estimates
from the same studies ranged between 7.4% (AOM) and 24.6%
(secretory OM) [49,55,76,80], with 3 percentage estimates 20%
[55,76,80]. S. aureus estimates from 5 studies ranged from 4% to
25% [49,55,64,76,80], with reasonable consistency seen within 3 of
the studies with percentage estimates >19% [49,76,80].
Bulut et al. was the only study found to describe viral isolates of
AOM in children <6 years of age in Turkey [55]. Among children
aged 6–24 months, 26% (13/50) were infected with respiratory
syncytial virus (RSV) and 12% (6/50) were infected with human
rhinovirus (HRV) (2 children were positive for both RSV and HRV)
[55].
Table 2
Summary of studies reporting counts or incidence of chronic and other OM for children <6 years of age.
Region Country (study design) N Diagnosis Age; count (%) Source
Africa Egypt (cross-sectional) 75,789 OM <2m; 258/3145 (8.2%)
2–11m; 2413/22,649 (10.7%)
1–4 y; 5407/49,995 (10.8%)
[24]
Nigeria (case series) 74 CSOM 1–5 y; 41/74 (55.4%) [58]
Nigeria (cross-sectional) 500 OM 0–5 y; 69/88 (78.41%) [59]
569 OME <5 y; 185/569 (32.5%) [60,61]
600 OM <1 y; 10/69 (14.5%)
1–4 y; 55/245 (22.45%)
[23]
375 CSOM 0–5 y; 109 specimens positive
for bacterial isolates
[62]
703 OM 0–6 y; 42/144 (29.2%) [63]
361 CSOM 0–1 y; 35/83 (42.2%)
2–5 y; 98/151 (64.9%)
[53]
Ethiopia (cross-sectional) 112 CSOM <2 y; 43 cases
2–4 y; 20 cases
[64]
391 CSOM <6m; 5/167 (3%)
6–11m; 17/167 (10.2%)
12–23m; 50/167 (29.4%)
24–59m; 95/167 (58.9%)
[65]
Coˆte d’Ivoire (cross-sectional) 653 OM 0–4 y; 15.3% [66]
India and South Asia India (cross-sectional) 296 CSOM 2–5 y; 17/296 (5.7%) [67]
100 OM 1 m–3 y; 5/100 (5%) [68]
800 OM <1 y; 1/8 (12.5%)
1–2 y; 11/83 (13.3%)
2–3 y; 14/161 (8.7%)
3–4 y; 13/170 (7.6%)
4–5 y; 15/165 (9.1%)
[27]
278 CSOM 0–2 y; 29 cases [69]
Bangladesh (case series) 252 CSOM NR; 19/252 (7.5%) [3]
Bangladesh (cross-sectional) 203 CSOM <1 y; 2/12 (17%)
2–5 y; 8/62 (13%)
[70]
Pakistan (cross-sectional) 197 Exudative OM <1 y; 8 cases [71]
87 Secretory OM 2–4 y; 9 cases [72]
156 CSOM <1 y; 55 casesa
1–5 y; 45 casesa
[73]
China and Hong Kong China (cross-sectional) 2902 OME 2–3 y; 8/57 (14%)
3–4 y; 38/457 (8.2%)
4–5 y; 18/364 (5%)
5–6 y; 27/553 (4.9%)
[26]
7469 OME 3 y; 90/742 (12.13%)
4 y; 162/3101 (6.93%)
5 y; 200/3250 (6.46%)
[25]
Hong Kong (cross-sectional) 797 Secretory OM 2–3 y; =66 (21.6%)b
4–5 y; =35 (7.1%)b
2–3 y; =94 (30.7%)c
4–5 y; =68 (13.8%)c
[74]
Middle East Saudi Arabia (cross-sectional) 1800 OM <5 y; 463 cases [75]
OM (complications) <5 y; 45 cases
321 Secretory OM 0–4 y; 47 cases [76]
1077 OME 5–6 y; 16/105 (15.2%) [77]
Oman (cross-sectional
state surveillance)
NR COM <5 y; 2951 cases [31]
NR COM <5 y; 2478 cases [32]
NR COM <5 y; 2074 cases [33]
NR COM <5 y; 1633 cases [34]
NR COM <5 y; 981 cases [56]
654 Secretory OM 98/654 (15%)
Supp. OM 33/654 (5%)
NR OM <4 y; 748 (per 10,000) [35]
NR COM <5 y; 722 cases [36]
688 Secretory OM 83/688 (12.1%)
Supp. OM 51/688 (7.4%)
NR OM <4 y; 658 (per 10,000) [37]
UAE (cross-sectional) 739 OM 0–5 y; 21/739 (2.8%) [78]
Iran (cross-sectional) 1833 OME 2–6 y; 167/1833 (9.1%) [30]
856 Serious OM 0–6 y; 31% [79]
Bahrain (cross-sectional
hospital surveillance)
188 Non-supp.OM <1 y; 1/188 discharges [38]
157 Non-supp.OM <1 y; 5/157 discharges [39]
109 Supp. & unsp. OM <1 y; 26/109 discharges [40]
242 Non-supp.OM <1 y; 6/242 discharges
149 Supp. & unsp. OM <1 y; 22/149 discharges [41]
129 Non-supp.OM <1 y; 1/129 discharges
185 Supp. & unsp. OM <1 y; 18/185 discharges [42]
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Table2 (Continued )
Region Country (study design) N Diagnosis Age; count (%) Source
110 Non-supp. OM <1 y; 1/110 discharges
123 Supp. & unsp. OM <1 y; 13/123 discharges [43]
102 Non-supp. OM <1 y; 4/102 discharges
132 Supp. & unsp. OM <1 y; 24/132 discharges [44]
119 Non-supp. OM <1 y; 2/119 discharges
105 Supp. & unsp. OM <1 y; 8/105 discharges [45]
97 Non-supp. OM <1 y; 5/97 discharges
103 Non-supp. OM <1 y; 1/103 discharges [46]
92 Non-supp. OM <1 y; 8/92 discharges [47]
Russia and CIS Russia (cross-sectional) 130,278d All types 0–7 y; 13.6 (per 1000)
<1 y; 9.3 (per 1000)f
1–3 y; 7.2 (per 1000)f
4–7 y; 15.5 (per 1000)f
<1 y; 12.3 (per 1000)g
1–3 y; 10.3 (per 1000)g
4–7 y; 17.3 (per 1000)g
[48]
115,828e 0–7 y; 34.5 (per 1000)
<1 y; 51.2 (per 1000)f
1–3 y; 32.1 (per 1000)f
4–7 y; 32.9 (per 1000)f
<1 y; 49.8 (per 1000)g
1–3 y; 38.4 (per 1000)g
4–7 y; 29.4 (per 1000)g
OM, otitis media; COM, chronic otitis media; CSOM, chronic suppurative otitis media; OME, otitis media with effusion; N, sample size; supp., suppurative; unsp., unspeciﬁed;
m, month; y, year; NR, not reported; UAE, United Arab Emirates.
a Read from a graph.
b Otoscopic diagnosis.
c Tympanometric diagnosis.
d 1991.
e 1996.
f Males.
g Females.
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Only few studies reported on antimicrobial resistance for OM
patients <6 years of age [49,80]. In Nigeria, Ako-Nai et al. [49]
reported on the high levels of resistance for all 35 isolates, including
S. pneumoniae, H. inﬂuenzae and S. aureus, to one or more antibiotics
(74.2% resistant to penicillin, 62.8% to streptomycin, 57.0% to
gentamicin, 68.0% to chloramphenicol, and 77.7% to nalidixic acid).
All 35 isolateswere sensitive to oﬂoxacin [49]. Similarly, Guven et al.
[80] reported on the considerable resistance to penicillin amongst
the same pathogens in Turkey (22/46 (48%) S. pneumoniae, 16/24
(67%) of H. inﬂuenzae and 8/16 (50%) S. aureus isolates). All of these,
except for 4/16 (25%) S. aureus isolates, were susceptible to
amoxicillin-clavulanate. They also note that a signiﬁcant proportion
(40%)ofbacteria resistant topenicillincamefromchildren2years
of age [80]. Again, both studies were conducted before PCVs being
introduced in NIPs (Nigeria–end of 2014, Turkey–end of 2008) [81].
4. Discussion
This review has investigated the epidemiology, etiology and
antibiotic resistance of OM across 90 developing and newly
industrialised countries and found that OM remains associated
with a high disease burden and costs for the payer and for the
society. These data are valuable for vaccine decision-makers to
evaluate the potential health impact of vaccines in their countries.
They are also relevant in the context of antibiotic treatment and
potential antibiotic resistance. The current review covered a
variety of outcomes relating to OM including incidence and
prevalence, distribution of causing pathogens and antimicrobial
resistance. However, the relative paucity of data and the
heterogeneity on study designs, OM case deﬁnitions and settings
where most of the literature was identiﬁed, made generalisations
very difﬁcult and conclusions should be drawn with caution.In total, 59 publications were included in the review, covering
the 1992–2011 period. Thismight be the best evidence considering
prospective follow-up at population level. These publications were
found to address the question of OM count and/or prevalence and/
or incidence in the relevant countries. Several population-based
studies were found [23–27], along with single-centre studies
which used relatively large samples [28–30]. Oman and Bahrain
were well-served by health system or hospital surveillance data
whichwas reported consecutively over several years [31–47]. Data
coverage was featuring prominently within some countries like
Nigeria, while others, like Russia, had only one study reporting data
from one city [48].
A number of reviewswere recently published, assessingOMdata
inchildren fromdifferent regionsof theworld [2,4,5]. Ina systematic
review aimed to provide global estimates for OM and related
conditions, the AOM incidence rate was estimated at 10.85%
(709 million cases each year, 51% of these occurring in <5 year-
olds) [4]. In another review, Bardach et al. reported an incidence
range for AOM of 1171–36,000 episodes/100,000 children, for
children aged<5 years of age from Latin America and the Caribbean
[2]. In Asia Paciﬁc countries, OM prevalence in school-age children
was reported to vary between 3.25% (Thailand) and 12.23%
(Philippines) [5].
Our results are inagreementwithrecentlypublisheddata [2,4,5];
the reported prevalence of OM in population-based studies was
between 6.3% and 10.7%. In several studies included in the review,
the OM prevalence values were higher at younger ages (<3 years of
age) [23,24,26,27]. The reported values included here are however
much lower than those from comparable studies in other world
regions. Auinger et al. reported the prevalence of OM in the US from
1988–1994 for children <6 years of age to be 68.2% (95% CI: 66.3%,
70.1%) [1]. The prevalence of early onset of OM (<1 year of age) was
reported to be 56.8% (95% CI: 52.9%, 60.7%), while repeated OM
prevalence was 36.1% (95% CI: 32.8%, 39.3%) [1].
Table 3
Summary of included studies reporting the distribution of pathogens and isolates causing OM in children <6 years of age.
Region Country (study
design; year)
N Diagnosis Pathogens isolated PCV introduction
(year)
Source
Africa Nigeria
(cross-sectional;
2002)
617 (53a) AOM S. pneumoniae; 6/68b (8.8%)
H. inﬂuenzae; 5/68 (7.4%)
S. aureus; 17/68 (25%)
Bacillus spp; 10/68 (14.7%)
Corynebacterium spp; 3/68 (4.4%)
P. mirabilis; 11/68 (16.2%)
P. aeruginosa; 5/68 (7.4%)
K. oxyotoca; 4/68 (5.9%)
Citrobacter spp; 1/68 (1.4%)
2014 (phasedc) [49]
Ethiopia
(cross-sectional;
2001)
63d CSOM S. aureus; 9 (8.0%) single, 4 (3.6%) mixed
P. mirabilis; 12 (10.7%) single, 8 (7.1%) mixed
E. coli; 6 (5.3%) single, 6 (5.3%) mixed
Klebsiella; 3 (2.7%) single, 5 (4.5%) mixed
Others: 7 (6.2%) single, 10 (8.9%) mixed
2011 [64]
India and South Asia India
(cross-sectional;
2004)
278 CSOM P. aeruginosa; 3/29c (10.3%)
S. aureus; Klebsiella and Citrobacter (NA)
No decision [69]
Middle East Turkey
(case series;
2006–2007)
120 AOM S. pneumoniae; 18 (36%)
H. inﬂuenzae; 8 (16%)
S. aureus; 2 (4%)
M. catarrhalis; 1 (2%)
E. coli; 2 (4%)
2008 [55]
180 AOM S. pneumoniae; 16/42e (38%)
H. inﬂuenzae; 10/42e (24%)
S. aureus; 8/42e (19%)
[80]
Saudi Arabia
(cross-sectional;
1998)
321 Secretory OM S. aureus 15 (24.6%)
H. inﬂuenzae; 15 (24.6%)
Pseudomonas spp; 9 (14.8%)
Proteus spp; 1 (1.6%)
S. pneumoniae 6 (9.8%)
S. pyrogenes 4 (6.6%)
Others 3 (4.9%)
2009 [76]
a Children with AOM.
b Number of isolates.
c Children <2 years of age.
d Children <4 years of age.
e Children <2 years of age for which bacteria were isolated.
OM, otitis media; AOM, acute otitis media; CSOM, chronic suppurative otitis media; OME, otitis media with effusion; N, sample size; NA, not available
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review (1992–2011) were very limited. However, more recent
data are currently available. For example, a review published in
2014 evaluated the pneumococcal serotype distribution in Russia
[83]. In one of the studies included in that review, the incidence of
severe AOM (requiring tympanocentesis) was reported at 12.2 per
1000 in children <3 years old, and 9.7 per 1000 children 4–7 years
old from Saint Petersburg [83]. Another very recent study from
Kenya [84], which included 13.109 children <15 years of age
(1702<6 years of age) from58urban and rural schools, reported the
following OM rates (per 1000 children [with 95% conﬁdence
intervals]) in children <6 years of age: AOM urban, 19.3 (6.3–
45.1); AOM rural, 27.7 (19.1–36.3); OME urban, 54.1 (25.7–82.4);
OME rural, 35.3 (25.6–45); CSOM urban, 30.9 (13.3–60.8); CSOM
rural, 12.5 (6.7–18.2).
For the current review, only 6 studies (5 AOMand 1 CSOM)were
found to address the bacterial etiology of OM in children<6 years of
age [49,55,64,69,76,80]. It should be noted that all resultswere based
on a small number of cases. Some overlap in results was identiﬁed
between the estimates of S. pneumoniae, H. inﬂuenzae and S. aureus
in Nigeria, Turkey and Saudi Arabia: S. pneumoniae estimates in
children with AOM were reported between 8.8% [49] and 36–38%
[55,80]; H. inﬂuenzae prevalence was reported at 16–24.6% in
3 studies (2 AOM and 1 CSOM) [55,76,80]; and S. aureus estimates
were between 19–25% in 3 studies (2 AOM and 1 CSOM) [49,76,80].
In addition to the 6 studies initially included in this review,
2 very recent papers (outside the screening period) reported on thebacterial etiology and the antimicrobial susceptibility of AOM in
children from China [85] and Saudi Arabia [86]. In the Chinese
study of children <18 years of age, Ding et al. reported that the
leading cause of AOM was S. pneumoniae (47.2%; 108/229),
followed by S. aureus (18.8%; 43/229) and H. inﬂuenzae (7.4%;
17/229) [85]. In Al-Mazrou et al. 21% (14/66) of AOM episodes
recorded in Saudi children 3–60 months of age were positive for
either S. pneumoniae or NTHi and 26% (17/66) for S. aureus. The
authors suggested that even if S. aureus is an uncommon cause of
AOM, it might become an important contributor to AOM in these
regions following the introduction of routine pneumococcal
vaccination [86]. Importantly, the relative consistency seen within
3 of our included studies [49,76,80], highlight the importance of
screening for S. aureus as a pathogen in AOM.
In comparison with the data reviewed here, a systematic review
by Coker et al. included 6 studies undertaken in the US, Finland, and
the Netherlands [20]. These studies reported percentage estimates
of pathogens causing AOM, in children 4 weeks to 18 years of age,
ranging from 23% to 48% for S. pneumoniae and 41% to 57% for
H. inﬂuenzae. Bardachet al. estimated that S. pneumoniae (32.4%) and
H. inﬂuenzae (26.0%) including NTHi (18.3%), were the most
prevalent AOM bacterial pathogens in children <6 years of age
from Latin America and the Caribbean [2]. In this meta-analysis,
S. aureus prevalence was estimated at only 2.77% [2].
Antimicrobial resistance is a major problem in countries with
higher density populations where antibiotics are easily obtained
over the counter [87,88]. For example, in China, India and Nigeria,
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wealthy middle class individuals [89]. Therefore, concerns still
remain about combating the spread of antimicrobial resistance
especially in children with pneumonia and OM.
Concerning antimicrobial resistance, only 2 studies included in
the current review reported data from OM samples for children<6
years of age. Ako-Nai et al. and Guven et al. reported high levels of
resistance to penicillin [49,80]. Similarly, in the recent aforemen-
tioned study from China, the antibiotic resistance rates of
S. pneumoniae isolates to erythromycin were 99.1%, and the
non-susceptibility rate to penicillin was 54.6% [85]. In another
recent study from Russia, the rate of multidrug-resistant pneumo-
cocci was reported at 22%, while the resistance rate to penicillin
and erythromycin was 28% and 26%, respectively [90].
A recent study from South Africa suggests that managing co-
morbidities associatedwith CSOM (malnutrition, HIV infection and
anemia), especially in children from Africa, can signiﬁcantly
improve the treatment outcomes [91]. This study points out the
fact that all children presenting with CSOM should receive a
comprehensive clinical examination, with a nutritional assess-
ment, an HIV test and other clinical investigations [91]. Moreover,
as shown in a recent systematic review, early breastfeeding,
smoking avoidance during and after pregnancy, and reduction of
exposure to indoor air pollution are crucial in prevention of AOM
and its complications and sequelae [4].
PCVs have been shown to have a direct impact against OM
[92–94]. Moreover, the development and widespread use of
H. inﬂuenzae type b (Hib) conjugate vaccines have nearly
eradicated invasive Hib disease in children in countries where
the vaccines are used widely [95]. However, the majority of H.
inﬂuenzae strains currently causing AOM are NTHi. Interestingly, a
PCV incorporating a carrier protein (protein D) derived from NTHi
was shown to have modest efﬁcacy against NTHi AOM [93,94].
A recent study from the US aimed to determine the microbiolo-
gy of OM in children at 2–3 years post-introduction of the 13-
valent pneumococcal conjugate vaccine (PCV13) in February 2010
[96]. A single (1/39) non-vaccine S. pneumoniae (serotype 16)
isolate was obtained from a 7-valent pneumococcal (PCV7)-only
vaccinated patient and was penicillin susceptible, indicating that
PCV13 has had a signiﬁcant impact on pneumococcal infections
during these initial years following licensure [96]. Concerning the
impact of PCV7, a systematic review by Taylor et al. concluded that
this vaccine provides some protection against OM, but more data
with comparisons pre- to post-vaccination are needed to estimate
the true impact of vaccination on AOM [97].
Although these data are essential, as of December 2012, PCV
was introduced into the NIP in only 44% (86/194) of the WHO
member states, with 41% (19/46) of member states in the African
Region, 33% (9/27) of member states in theWestern Paciﬁc Region,
and none of 11member states in the South East Asia Region [98]. As
of 2015, 127 countries (65%) have introduced PCV into their NIP
(including 119 universal, 2 phased, and 6 at-risk programs) and
23 additional countries have announced plans to introduce PCV
into their NIP [81]. A summary of the ﬁndings on the availability of
pneumococcal and Hib vaccinations in the relevant countries
considered for the current review is presented in Supplementary
materials, Appendix D. This informationwasmainly obtained from
aWHO/UNICEF survey in 2011 [99]; additional resources included
country-speciﬁc ministry of health websites.
The strength of this review lies in its adherence to established
methods for conducting systematic reviews, extensive searching,
an inclusive date range, and the searching, screening and inclusion
of multi-language papers, combined with a quality assessment of
the included studies. Compiling all available evidence on this
matter will help stakeholders to make informed decisions on
prevention measures.However, our review has several limitations. Firstly, therewas a
lack of reliable data, mainly associated with the variability in case
deﬁnitions for OM, to conﬁdently address the research questions
for the relevant countries. Few studies were population-based or
reported estimates for incidence or prevalence. Instead, most
provided one-off measures of OM for a single site over a single
timepoint. Most studies also only included small or modest sample
sizes. The included studies employed different study designs
including parental reports of physician’s diagnosis; recall bias is
always a potential factor in survey questionnaires. The studies
used a variety of means to diagnose OM and included a wide range
of OM case deﬁnitions, leading to overestimation of reported
prevalence. Due to the heterogeneity in reporting the outcomes,
statistical pooling or a meta-analysis could not be performed.
Another limitation of this review relates to the screening of titles
and abstracts. Given the volume of results to be screened we
frequently relied on the ﬁrst author’s correspondence address as a
means of judging whether the study was conducted in a country of
interest when it was not clear from the title or abstract. Finally, a
further limitation of this review is that 75 full papers could not
be retrieved, despite extensive efforts. It is difﬁcult to assess
the impact of not having seen these papers, though based on the
exclusion pattern it seems likely thatmanywould not havemet the
inclusion criteria.
While there are clear and substantial obstacles to undertaking
research in many of the countries included in this review, future
studies should endeavour to be population-based and/or provide
repeated measures to add further reliability to the data. When
studies include a broad age range (children and adults), it would be
beneﬁcial to report the results for adults and children separately,
as the health implications may vary depending on the age group.
Future studies should also aim to use strict and harmonized OM
diagnostic criteria in assembling a sample and adequately report
this in publications. Studies of bacterial etiology and antimicrobial
resistance should include much larger samples to add further
reliability to the evidence-base.
5. Conclusions
The studies included in this review indicate that OM and its
various sub-types are prevalent and a burden across the
90 developing and newly industrialised countries. The data
presented provided an overview of the best available evidence
on the burden of OM data up to 2012, prior to Hib and
pneumococcal vaccines being widely used in these countries.
Although in the majority of these countries Hib and pneumococcal
vaccines have been licensed, only some countries have introduced
them in the NIP. These key data would be essential for any
discussion with decision makers within these countries on
potential introduction and impact of Hib and pneumococcal
conjugate vaccines in prevention of OM.
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